In PAN patients with cutaneous manifestations, Okano et al. suggested that anti-phosphatidylserine-prothrombin complex (anti-PSPT) antibodies could be regarded as a biomarker for the existence of PAN and therefore support making an early diagnosis (83). This evidence concerns the gene F2 and polyarteritis nodosa.